Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.71 |
| ▸ | TTR | P02766 | 5/20 | 0.71 |
| ▸ | EYA3 | Q99504 | 5/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | PGR | P06401 | 2/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.71 |
| ▸ | EYA2 | O00167 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26809506 | 0.93 | SLC22A12 (0.62) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL30258713 | 0.91 | SLC22A12 (0.70) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL26809440 | 0.90 | SLC22A12 (0.68) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL30258456 | 0.90 | SLC22A12 (0.68) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL30258897 | 0.90 | TTR (0.69) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL30258722 | 0.89 | SLC22A12 (0.67) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL26668789 | 0.84 | SLC22A12 (0.51) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| SCHEMBL26809488 | 0.84 | SLC22A12 (0.51) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| Benzbromarone SCHEMBL19205474 | 0.83 | SLC22A12 (1.00) | SLC22A12TTREYA3CYP2C19CYP2C9 | |
| Benzbromarone SCHEMBL29361528 | 0.83 | SLC22A12 (1.00) | SLC22A12TTREYA3CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282741-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INNOVO THERAPEUTICS INC. (KR) | 2025-09-11 | — | — | US | claimed |
| EP-4413981-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Innovo Therapeutics Inc. (KR) | 2024-08-14 | — | — | EP | claimed |
| CN-118043043-A | Benzofuranyl hydroxy phenyl ketone derivative compound or pharmaceutically acceptable salt thereof | 因诺沃治疗有限公司 | 2024-05-14 | — | — | CN | claimed |
| WO-2023059121-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | (주)이노보테라퓨틱스 | 2023-04-13 | — | — | WO | claimed |
| US-20250282741-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INNOVO THERAPEUTICS INC. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4413981-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Innovo Therapeutics Inc. (KR) | 2024-08-14 | — | — | EP | disclosed |
| CN-118043043-A | Benzofuranyl hydroxy phenyl ketone derivative compound or pharmaceutically acceptable salt thereof | 因诺沃治疗有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023059121-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | (주)이노보테라퓨틱스 | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282741-A1 | NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | HSPH1, HSP90AA1, HSPD1 | SLC22A12 815/4885TTR 1428/4885EYA3 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.